Search

Your search keyword '"Butchbach, Matthew E. R."' showing total 42 results

Search Constraints

Start Over You searched for: Author "Butchbach, Matthew E. R." Remove constraint Author: "Butchbach, Matthew E. R." Language english Remove constraint Language: english
42 results on '"Butchbach, Matthew E. R."'

Search Results

4. Biological networks and complexity in early-onset motor neuron diseases.

5. Comprehensive In Silico Analysis of Retrotransposon Insertions within the Survival Motor Neuron Genes Involved in Spinal Muscular Atrophy.

8. The effects of C5-substituted 2,4-diaminoquinazolines on selected transcript expression in spinal muscular atrophy cells.

9. SMN1 and SMN2 copy numbers in cell lines derived from patients with spinal muscular atrophy as measured by array digital PCR.

10. Systems Biology Investigation of cAMP Modulation to Increase SMN Levels for the Treatment of Spinal Muscular Atrophy.

11. Transcriptome Profiling of Spinal Muscular Atrophy Motor Neurons Derived from Mouse Embryonic Stem Cells.

12. Association of Excitatory Amino Acid Transporters, Especially EAAT2, with Cholesterol-rich Lipid Raft Microdomains.

13. Genomic Variability in the Survival Motor Neuron Genes (SMN1 and SMN2): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development.

14. Human Glioma Cells and Undifferentiated Primary Astrocytes That Express Aberrant EAAT2 mRNA Inhibit Normal EAAT2 Protein Expression and Prevent Cell Death

15. NF-κB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia.

16. Translational Control of Glial Glutamate Transporter EAAT2 Expression.

17. Effects of Inhibitors of SLC9A-Type Sodium-Proton Exchangers on Survival Motor Neuron 2 ( SMN2 ) mRNA Splicing and Expression.

18. Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data.

19. Using Systems Biology and Mathematical Modeling Approaches in the Discovery of Therapeutic Targets for Spinal Muscular Atrophy.

20. Establishing a reference dataset for the authentication of spinal muscular atrophy cell lines using STR profiling and digital PCR.

21. Effect of the Butyrate Prodrug Pivaloyloxymethyl Butyrate (AN9) on a Mouse Model for Spinal Muscular Atrophy.

22. Identification of early gene expression changes in primary cultured neurons treated with topoisomerase I poisons.

23. Applicability of digital PCR to the investigation of pediatric-onset genetic disorders.

24. Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy.

25. Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases.

26. The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy.

27. The effect of diet on the protective action of D156844 observed in spinal muscular atrophy mice.

29. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy.

30. Effect of diet on the survival and phenotype of a mouse model for spinal muscular atrophy.

31. Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: applicability to preclinical therapy development for spinal muscular atrophy.

32. Let all DNA vote: who are the amyotrophic lateral sclerosis candidates?

33. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.

34. Protein phosphatase 1 binds to the RNA recognition motif of several splicing factors and regulates alternative pre-mRNA processing.

35. Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs.

36. Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy.

37. A novel method for oral delivery of drug compounds to the neonatal SMNDelta7 mouse model of spinal muscular atrophy.

38. Translational control of glial glutamate transporter EAAT2 expression.

39. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia.

40. Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice.

41. Methyl-beta-cyclodextrin but not retinoic acid reduces EAAT3-mediated glutamate uptake and increases GTRAP3-18 expression.

42. Molecular cloning, gene structure, expression profile and functional characterization of the mouse glutamate transporter (EAAT3) interacting protein GTRAP3-18.

Catalog

Books, media, physical & digital resources